Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic impact of weight loss during first-line chemotherapy in extensive-disease small cell lung cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

M-Sec promotes the production of infectious HIV-1 virus through the exocyst complex in macrophages.

PLoS pathogens·2026
Same author

The gp120 Envelope Glycoprotein of HIV-1 Triggers Macropinocytosis in Primary CD4+ T Cells to Promote HIV-1 Infection.

bioRxiv : the preprint server for biology·2026
Same author

Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non-Small Cell Lung Cancer: A Single-Institution Retrospective Study.

Thoracic cancer·2026
Same author

Weight change and impact on prognosis in patients with advanced non-small cell lung cancer with concomitant diabetes mellitus treated with sglt2 inhibitors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Efficacy of Osimertinib in Patients With Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations.

Thoracic cancer·2026

Related Experiment Video

Updated: May 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K

Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line

Hiroaki Kodama1, Haruyasu Murakami1, Nobuaki Mamesaya1

  • 1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.

Thoracic Cancer
|November 17, 2025
PubMed
Summary

Advanced age and central nervous system (CNS) metastases prevent many patients with EGFR-mutated non-small-cell lung cancer from receiving subsequent therapy after osimertinib treatment.

Keywords:
CNS metastasisEGFR‐TKINSCLColder patientsosimertinib

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

Related Experiment Videos

Last Updated: May 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.4K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

Area of Science:

  • Oncology
  • Medical Oncology
  • Thoracic Oncology

Background:

  • Osimertinib is a third-generation EGFR-TKI improving survival in EGFR-mutated NSCLC.
  • A significant number of patients do not receive subsequent therapy (ST) after osimertinib.
  • Identifying barriers to ST is crucial for optimizing patient care.

Purpose of the Study:

  • To identify patient characteristics associated with ineligibility for post-osimertinib therapy.
  • To analyze reasons for discontinuation of osimertinib and lack of subsequent treatment.
  • To inform potential alternative first-line treatment strategies.

Main Methods:

  • Retrospective enrollment of patients with EGFR-mutated NSCLC receiving first-line osimertinib.
  • Categorization into ST and non-subsequent therapy (NST) groups.
  • Documentation of baseline characteristics, treatment outcomes, and reasons for discontinuation.

Main Results:

  • 39.4% of patients did not receive ST.
  • Advanced age and baseline CNS metastases were significantly associated with lack of ST (p < 0.01).
  • Worsening performance status, often due to CNS metastasis progression, was the primary reason for not receiving ST.

Conclusions:

  • Advanced age and baseline CNS metastases are key barriers to ST after osimertinib.
  • These factors may necessitate exploring alternative first-line treatment strategies.
  • Further research into optimizing treatment sequencing for specific patient subgroups is warranted.